drugset / Trial / NCT02443922
Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glimeperide Administration in Type 2 DM
Unknown
100 enrolled
Foundation for the National Institutes of Health
Amylin Pharmaceuticals, LLC. · collabEli Lilly and Company · collabJohnson & Johnson Pharmaceutical Research & Development, L.L.C. · collabJuvenile Diabetes Research Foundation · collabMerck Sharp & Dohme LLC · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabNovartis · collabPfizer · collabTakeda · collab
Non-randomizedParallel-groupOpen-label
Summary
A multi-year clinical study to improve tools for measuring the function of insulin-producing beta cells in people with type 2 diabetes mellitus.
Timeline
- Start
- 2015-06
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glimepiride | Small molecule | 2 mg | — |
| Subject | Sitagliptin | Small molecule | 100 mg | — |
| Background | Metformin | Small molecule | — | — |